WO2011111679A1 - タンパク質含有液処理用多孔質中空糸膜 - Google Patents
タンパク質含有液処理用多孔質中空糸膜 Download PDFInfo
- Publication number
- WO2011111679A1 WO2011111679A1 PCT/JP2011/055299 JP2011055299W WO2011111679A1 WO 2011111679 A1 WO2011111679 A1 WO 2011111679A1 JP 2011055299 W JP2011055299 W JP 2011055299W WO 2011111679 A1 WO2011111679 A1 WO 2011111679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hollow fiber
- fiber membrane
- membrane
- protein
- filtration
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 265
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 179
- 239000007788 liquid Substances 0.000 title claims abstract description 111
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 62
- 238000001914 filtration Methods 0.000 claims abstract description 114
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 96
- 239000000706 filtrate Substances 0.000 claims abstract description 49
- 241000700605 Viruses Species 0.000 claims abstract description 47
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 45
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 45
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 27
- 229920001600 hydrophobic polymer Polymers 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 98
- 239000012460 protein solution Substances 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 18
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
- 229920002492 poly(sulfone) Polymers 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 238000011085 pressure filtration Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 12
- 230000005540 biological transmission Effects 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 description 54
- 238000005345 coagulation Methods 0.000 description 49
- 230000015271 coagulation Effects 0.000 description 49
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 46
- 239000000126 substance Substances 0.000 description 35
- 238000000034 method Methods 0.000 description 34
- 239000011148 porous material Substances 0.000 description 33
- 238000001035 drying Methods 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 25
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 22
- 230000035699 permeability Effects 0.000 description 21
- 230000007423 decrease Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 238000000926 separation method Methods 0.000 description 19
- 238000005406 washing Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000004695 Polyether sulfone Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229920006393 polyether sulfone Polymers 0.000 description 12
- 241001515965 unidentified phage Species 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000005191 phase separation Methods 0.000 description 11
- 238000009987 spinning Methods 0.000 description 11
- 230000004907 flux Effects 0.000 description 10
- 238000007654 immersion Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000002834 transmittance Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 238000010335 hydrothermal treatment Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000012466 permeate Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000004627 regenerated cellulose Substances 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 241000702315 Escherichia virus phiX174 Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 230000001112 coagulating effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101100074988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001891 gel spinning Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000002145 thermally induced phase separation Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
- B01D69/081—Hollow fibre membranes characterised by the fibre diameter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
- B01D69/087—Details relating to the spinning process
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/44—Polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of groups B01D71/26-B01D71/42
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/44—Polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of groups B01D71/26-B01D71/42
- B01D71/441—Polyvinylpyrrolidone
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/08—Fully permeating type; Dead-end filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/02—Details relating to pores or porosity of the membranes
- B01D2325/026—Sponge structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/04—Characteristic thickness
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/20—Specific permeability or cut-off range
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/28—Degradation or stability over time
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/36—Hydrophilic membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/38—Hydrophobic membranes
Definitions
- the present invention relates to a porous hollow fiber membrane for protein-containing liquid treatment suitable for separating fine particles such as viruses contained in an aqueous fluid such as a protein solution.
- a porous hollow fiber membrane for protein-containing liquid treatment suitable for separating fine particles such as viruses contained in an aqueous fluid such as a protein solution.
- it preferably comprises a hydrophobic polymer and a hydrophilic polymer, has a pure water permeation rate of 10 to 300 L / (h ⁇ m 2 ⁇ bar), and a 0.5% immunoglobulin solution in a dead end.
- the present invention relates to a porous hollow fiber membrane for protein-containing liquid treatment, characterized in that the filtration time and the filtrate collection integrated amount are substantially linear when filtered at a constant pressure of 1.0 bar over a minute.
- Hollow fiber membranes for the treatment of aqueous fluids are widely used in industrial applications such as microfiltration and ultrafiltration, and medical applications such as hemodialysis, hemofiltration and hemodiafiltration.
- industrial applications such as microfiltration and ultrafiltration
- medical applications such as hemodialysis, hemofiltration and hemodiafiltration.
- pathogenic substances such as viruses from protein solutions, which are useful components, and improving safety.
- Non-Patent Document 1 regarding the virus removal / inactivation process of the plasma fraction preparation, it is desirable to work on two or more different virus inactivation and removal processes.
- the LRV to be achieved as the target value is about 4.
- Non-Patent Document 3 “Especially regarding the virus removal / inactivation process, in Japan,“ Guidelines on Ensuring the Safety of Plasma Fractionated Drugs against Viruses ”, Medicament No. 1047 (March 30, 1999)
- Virus clearance index R log ((V1 ⁇ T1) / (V2 ⁇ T2)) V1 Capacity before process treatment T1 Virus titer before process treatment V2 Capacity after process treatment T2 Virus titer after process treatment
- Virus removal and inactivation methods include heat treatment, optical treatment such as gamma rays and ultraviolet irradiation, chemical treatment such as low pH treatment, precipitation fractionation such as ethanol fractionation and ammonium sulfate fractionation, and removal by membrane filtration.
- optical treatment such as gamma rays and ultraviolet irradiation
- chemical treatment such as low pH treatment
- precipitation fractionation such as ethanol fractionation and ammonium sulfate fractionation
- removal by membrane filtration membrane removal methods that do not lead to protein denaturation have attracted attention in removing viruses from protein solutions.
- proteins that are useful components must be efficiently permeated and recovered.
- the target of separation and removal is a small-sized virus such as parvovirus, it has been difficult to satisfy the virus removal characteristics and the permeation characteristics of useful proteins at the same time.
- Patent Document 1 an average permeation rate for 5 minutes from the start of filtration when 3 wt% bovine immunoglobulin having a specific maximum pore size and the proportion of monomer is 80 wt% or more is filtered at a low pressure of 0.3 MPa.
- a hydrophilic microporous membrane in which the relationship between (globulin permeation rate A), average permeation rate for 5 minutes (globulin permeation rate B) after 55 minutes from the start of filtration, and maximum pore size is parameterized.
- the constituent requirements of this film are as follows. (1) Maximum pore size 10-100nm (2) Globulin permeation rate A> 0.0015 ⁇ maximum pore size (nm) 2.75 (3) Globulin permeation rate B / globulin permeation rate A> 0.2
- the requirement (1) merely describes the pore size required for removing infectious virus, as described in Patent Document 1, page 3, lines 21 to 27.
- the requirement of (2) requires that the globulin permeation rate A is larger than a certain value calculated from the maximum pore size of the micropores.
- the permeation of the protein solution Since it is obvious that a higher speed is preferable, only the target characteristics are described.
- the requirement of (3) requires that the permeation rate of the protein solution does not decrease with time, and this is also merely a description of the target characteristics required for a membrane intended to remove viruses from the protein solution.
- hydrophilic microporous membrane with a logarithmic removal rate of 3 or higher for porcine parvovirus, 3 wt% bovine immunoglobulin with a monomer content of 80 wt% or higher at low pressure filtration at 0.3 MPa, at the start of filtration
- hydrophilic microporous membranes with a cumulative permeation rate of 50 liters / m 2 or more after 3 hours are described in the subclaims. It only describes the target characteristics of membranes that are intended to remove viruses from protein solutions, and provides useful and specific information for the problem of obtaining membranes with high protein permeability and high virus removal. Do not mean.
- Patent Document 1 also discloses a microporous membrane having a coarse structure layer with a high porosity and a dense layer with a low porosity.
- a polyfluoride film that can easily form a homogeneous structure by thermally induced phase separation is disclosed.
- Hollow fiber membranes made of vinylidene chloride hereinafter abbreviated as PVDF
- this technology can be applied to materials such as polysulfone resins that are widely used as hemodialysis membrane materials due to their high water permeability. Is difficult to apply as is.
- Patent Document 2 discloses a microporous film having a coarse structure layer having a high porosity and a dense layer having a low porosity, but here, PVDF is also assumed as a material. PVDF is excellent in physical strength, but because it is a hydrophobic material, protein adsorption, membrane contamination and clogging are likely to occur, and the filtration rate drops rapidly. In order to improve this undesirable characteristic, it is necessary to impart hydrophilicity to the membrane. Generally, PVDF material membranes must be modified to hydrophilicity by post-treatment after film formation. As compared with a general polysulfone resin, forming a film in a blended state with a conductive polymer has a disadvantage in that it is a complicated manufacturing process.
- Patent Document 3 discloses a virus-retaining ultrafiltration membrane having an initial LRV of at least 4.0 relative to PhiX174 and having a surface hydrophilized with hydroxyalkylcellulose.
- the hydrophilicity is made by a special hydrophilic polymer, and lacks versatility.
- a blend of polysulfone or the like and a hydrophilic polymer such as polyvinyl pyrrolidone is also exemplified, but hydrophilic treatment with hydroxyalkyl cellulose is essential.
- a hollow fiber type is allowed as the membrane, a flat membrane type is assumed, and a sufficient explanation for obtaining the hollow fiber membrane type is not made.
- Patent Document 4 discloses a method for producing an immunoglobulin preparation that effectively removes viruses in industrial production processes and does not cause filtration problems such as clogging of the removal membrane due to aggregates and contaminating proteins. ing.
- a step of filtering an immunoglobulin solution using a porous membrane having an average pore diameter of 15 to 20 nm is included, and that the material of the porous membrane is preferably regenerated cellulose.
- [FIG. 1], [FIG. 2], and [FIG. 3] show graphs in which the accumulated filtrate amount extends almost linearly with respect to the elapsed time.
- the in-plane porosity initially decreases as it goes from the inner wall surface to the inside of the wall, and after passing through at least one minimum portion, the polymer porous hollow fiber having a pore structure that increases again at the outer wall portion
- a membrane and a virus removal method using this membrane to filter an aqueous protein solution are disclosed. If the membrane structure disclosed here is simply expressed, it can be said that the pore diameter of the membrane wall is a hollow fiber membrane having sparse-dense-sparse in the film thickness direction. Having such a tilted structure and having a specific average pore size is said to be suitable for removing proteins with high efficiency and for recovering proteins with high permeability without denaturing the proteins.
- various polymer substances are exemplified as the material, is a technology using regenerated cellulose, and it is difficult to apply the technology disclosed here to many materials for general use. Further, the disadvantages of the cellulose material are as already described.
- An object of the present invention to efficiently remove and remove a removal substance such as a virus contained in a solution, and at the same time, a useful recovery substance such as a protein efficiently permeates, and the permeation characteristics of the protein are less reduced over time.
- An object of the present invention is to provide a porous hollow fiber membrane for treating a liquid containing liquid.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention is (1) Containing hydrophobic polymer and hydrophilic polymer, pure water permeation rate is 10 ⁇ 300L / (h ⁇ m 2 ⁇ bar), and 0.5% immunoglobulin solution over 60 minutes with dead end When filtration is performed at a constant pressure of 1.0 bar, the filtration time and the filtrate collection integrated amount are substantially in a linear relationship.
- the central region of the film thickness portion has a substantially homogeneous structure, and the film thickness portion has a structure having no macrovoids.
- the inside diameter is 150 to 400 ⁇ m and the film thickness is 40 to 200 ⁇ m.
- the hydrophobic polymer is a polysulfone polymer.
- the hydrophilic polymer is polyvinylpyrrolidone.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention can be used for virus separation from a protein solution.
- the virus can be efficiently removed, and at the same time, the protein can permeate efficiently, Since the permeation characteristic does not drop over time, it can be preferably used as a membrane for removing pathogenic substances such as viruses from protein solutions that are useful components in the production process of biopharmaceuticals and blood products.
- a range indicated by a double-pointed arrow at the center of the image is “a central region of the film thickness portion”, and a range indicated by double-sided arrows on both sides is an inner surface side region and an outer surface side region of the film thickness portion.
- a range indicated by a double-pointed arrow at the center of the image is “a central region of the film thickness portion”, and a range indicated by double-sided arrows on both sides is an inner surface side region and an outer surface side region of the film thickness portion. It is an example of a structure where the central region is inhomogeneous.
- a range indicated by a double-pointed arrow at the center of the image is “a central region of the film thickness portion”, and a range indicated by double-sided arrows on both sides is an inner surface side region and an outer surface side region of the film thickness portion. It is an example of a structure where the central region is inhomogeneous.
- a range indicated by a double-pointed arrow at the center of the image is “a central region of the film thickness portion”, and a range indicated by double-sided arrows on both sides is an inner surface side region and an outer surface side region of the film thickness portion. This is an example of a structure in which the central region is inhomogeneous and has macrovoids.
- a range indicated by a double-pointed arrow at the center of the image is “a central region of the film thickness portion”, and a range indicated by double-sided arrows on both sides is an inner surface side region and an outer surface side region of the film thickness portion.
- 3 is a graph showing the relationship between immunoglobulin filtration time measured using the hollow fiber membranes obtained in Examples 1 to 7 and throughput.
- 3 is a graph showing the relationship between immunoglobulin filtration time measured using the hollow fiber membranes obtained in Comparative Examples 1 to 4 and throughput.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention comprises a hydrophobic polymer and a hydrophilic polymer.
- the hydrophobic polymer include polyester, polycarbonate, polyurethane, polyamide, polysulfone (hereinafter abbreviated as PSf), polyethersulfone (hereinafter abbreviated as PES), polymethyl methacrylate, polypropylene, polyethylene, PVDF, and the like.
- PSf polysulfone
- PES polyethersulfone
- polymethyl methacrylate polypropylene
- polyethylene polyethylene
- PVDF polyethylene
- polysulfone-based polymers such as PSf and PES having repeating units represented by the following chemical formulas 1 and 2 are advantageous and preferable for obtaining a highly water-permeable membrane.
- the polysulfone polymer referred to here may contain a substituent such as a functional group or an alkyl group, and the hydrogen atom of the hydrocarbon skeleton may be substituted with another atom such as halogen or a substituent. These may be used alone or in combination of two or more.
- hydrophilic polymer in the present invention examples include polymeric carbohydrates such as polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone (hereinafter abbreviated as PVP), carboxymethyl cellulose, and starch.
- PVP polyvinyl pyrrolidone
- carboxymethyl cellulose examples include starch.
- PVP polyvinyl pyrrolidone
- Luvitec (trade name) K17, K30, K60, K80, K85, K90 and the like commercially available from BASF are preferable, and Luvitec (trade name) K60, K80, K85, K90 and the like are more preferable.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention is characterized in that the permeation rate of pure water (hereinafter abbreviated as pure water Flux) is 10 to 300 L / (h ⁇ m 2 ⁇ bar).
- Pure water Flux is a measure of the pore size of the porous membrane. If the pure water flux is smaller than the above numerical value, the pore diameter becomes excessively small, and it becomes difficult to efficiently permeate the protein. Moreover, since the amount of water permeation is small, the efficiency of collecting the filtrate decreases. If the pure water Flux is larger than the above numerical value, the pore diameter becomes excessively large, and it becomes difficult to efficiently remove and remove a removal substance such as a virus.
- the pure water flux is more preferably 40 to 230 L / (h ⁇ m 2 ⁇ bar), and further preferably 70 to 230 L / (h ⁇ m 2 ⁇ bar).
- the protein which is a component to be recovered in the filtrate, exhibits high permeability through the filtration process. It is difficult to determine how much transmittance is required depending on the use, type, concentration, etc. of the protein, but it is generally preferably 95% or more. Below 95%, protein loss due to filtration increases and productivity decreases. In the membrane filtration, as the filtration time becomes longer, there is a possibility that the transmittance decreases due to clogging. Therefore, the transmittance (permeability retention rate) at the time of performing filtration for a sufficiently long time with respect to the transmittance at the initial stage of the filtration process is an index indicating the stability of protein permeation over time. Considering that the transmittance may decrease with time and that the transmittance is preferably at least 95% throughout the entire filtration process, the transmittance retention is preferably at least 95%.
- the process of, so to set the maximum filtration load applied to the film in about 50 ⁇ 200L / m 2 is generally 1/2 i.e. at least 50L / m 2, subjected to filtration loading of about 25L / m 2 It can be said that it is appropriate to consider that time.
- the concentration of the protein solution to be treated has been increasing in recent years. Therefore, when considering protein permeability, it is necessary to judge at a concentration of about 0.5% or more. It is reasonable.
- the filtration time and the filtrate collection integrated amount are substantially linearly related. It is characterized by that.
- the filtrate recovery amount tends to decrease with time due to clogging of the pore diameter.
- the filtrate collection integrated amount is plotted on the vertical axis, both have a convex curve relationship.
- the fact that the filtration time and the filtrate collection integrated amount are in a linear relationship means that the initial filtration characteristics are stably maintained even when filtration is continued, and no membrane defect occurs during filtration.
- a membrane having such filtration characteristics is preferable in that the efficiency of work can be expected because the filtration time required for the filtration treatment of a predetermined amount of liquid can be easily estimated.
- the separation characteristics at the initial stage of filtration are maintained even if filtration is continued, which is preferable in that the separation of the recovered substance and the removed substance is reliably achieved.
- substantially linear relationship means that the regression time obtained by the least square method from each point when the filtration time is plotted on the horizontal axis and the filtrate collection integrated amount is plotted on at least 6 points on the horizontal axis.
- R 2 is 0.95 or more. If it is lower than this, it means that the amount of filtrate recovered decreases with time due to protein clogging, which is not preferable. Since R 2 is 1 when the filtration time and the filtrate collection integrated amount are in a completely proportional relationship, the maximum value is 1 by default.
- the number of plots is preferably as large as possible in order to clarify the relationship between the filtration time and the filtrate recovery amount, but it is not preferable to increase the number of plots from the viewpoint of simplicity of measurement.
- the present invention is characterized in that the filtration time of the immunoglobulin solution and the filtrate collection integrated amount are substantially linearly related, but on the premise that the membrane area during filtration is unchanged, the per unit membrane area
- the filtrate collection integrated amount (hereinafter referred to as throughput) may be used instead of the filtrate collection integrated amount. By using the throughput, it is preferable because the filtrate recovery amounts measured at different membrane areas can be compared in the same row.
- the immunoglobulin used at this time is an immunoglobulin preparation for intravenous injection (hereinafter referred to as IVIG), specifically, a polyethylene glycol-treated human immunoglobulin, such as blood donated venoglobulin, because of its availability and stability of quality.
- IVIG immunoglobulin preparation for intravenous injection
- a polyethylene glycol-treated human immunoglobulin such as blood donated venoglobulin, because of its availability and stability of quality.
- -IH Yoshitomi is preferably used.
- IVIG has an incomplete molecular type containing an immunoglobulin fragment as an active ingredient and a complete molecular type containing immunoglobulin itself as an active ingredient.
- the latter is preferably used.
- the latter is preferably used.
- IVIG is often supplied as a solution with a concentration of about 5%, or a kit that can dissolve a lyophilized component to obtain a solution with a concentration of about 5%. In the present invention, this is diluted to 0.5%. It is preferred to use.
- the diluent used at this time is preferably phosphate buffered saline (hereinafter abbreviated as PBS).
- PBS phosphate buffered saline
- the phosphate buffered saline (hereinafter abbreviated as PBS) referred to in the present invention means an isotonic saline solution to which a buffering action is imparted by a phosphate, and the pH is preferably 6.5 to 7.5.
- the filtration experiment for obtaining the relationship between the filtration time of the immunoglobulin solution and the filtrate collection integrated amount is obtained under the following measurement conditions. Adjust the liquid temperature to 25 ° C. (1) Dilute IVIG to 0.5% with PBS and adjust pH to 6.8. (2) The solution is introduced into a hollow fiber membrane in a dry state, and filtered at a constant pressure of 1.0 bar for 60 minutes. (3) Record the filtration time and the filtrate recovery amount at almost equal intervals from the start to the end of filtration (eg, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes from the start of filtration). . (4) Divide the filtrate recovery amount by the membrane area to calculate the throughput. (5) filtration time, type a number of throughput spreadsheet software on a personal computer to calculate the R 2.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention preferably has a structure in which the central region of the film thickness portion has a substantially homogeneous structure and does not have macrovoids.
- the ⁇ central area of the film thickness part '' is a position on the outer surface side by a distance corresponding to 20% of the film thickness from the inner surface and a position on the inner surface side by a distance corresponding to 20% of the film thickness from the outer surface.
- substantially homogeneous structure means that the structure non-uniformity cannot be confirmed when a 1000 times SEM image is visually observed.
- the structure as shown in FIGS. 1 and 2 is “a structure in which the central region of the film thickness portion is substantially homogeneous”.
- the central region is sparse-dense from the inner surface toward the outer surface
- the central region is dense-sparse-dense from the inner surface toward the outer surface.
- the dense structure has changed in a complex manner. All of these are unfavorable structures in the present invention.
- the range indicated by the double-pointed arrow in the center of the image is the “central region of the film thickness portion”, and the range indicated by the double-sided arrows on both sides is the inner surface side region and the outer surface side region of the film thickness portion. It is.
- ⁇ having no macrovoids '' means that when a SEM image (1000 times) obtained by photographing five different areas of a film thickness portion is visually observed, a uniform film thickness portion is observed in any field of view. It means that a void region where a real part of the film is missing in a circular shape, an elliptical shape or a saddle shape as compared with the structure, that is, a macro void is not observed.
- a homogeneous membrane is preferably used to separate viruses from coexisting solutions that are not extremely different in size, such as separation and removal of small-diameter viruses from immunoglobulin solutions. This is because by taking a homogeneous structure in the thickness direction, it is possible to expect a pseudo multistage effect in which separation is repeated many times in many layers. In addition, with such a structure, even if there is a defect in a part of the film thickness part and the substance to be removed is not trapped there, there is a high possibility that it will be stopped somewhere in the film thickness part. In addition, the risk of leakage of a substance to be removed can be reduced as a whole film. Such a merit can be obtained because the central region has a homogeneous structure, which is suitable for removing substances such as viruses from protein solutions. The presence of macro voids is not preferable because it narrows the region where such an effect can be expected.
- the porous hollow fiber membrane for protein-containing liquid treatment according to the present invention may be provided at the time of filtration, although the filtration upstream side may be the hollow fiber membrane lumen side or the hollow fiber membrane outer wall side. From the viewpoint of durability against pressure, it is preferable to filter from the inner side to the outer side with the hollow fiber membrane lumen side as the upstream side of filtration.
- the inner diameter of the porous hollow fiber membrane for protein-containing liquid treatment of the present invention is preferably 100 to 1000 ⁇ m, more preferably 120 to 800 ⁇ m, further preferably 150 to 400 ⁇ m, and still more preferably 180 to 300 ⁇ m.
- the film thickness is preferably 10 to 500 ⁇ m, more preferably 20 to 400 ⁇ m, even more preferably 40 to 200 ⁇ m, and even more preferably 50 to 100 ⁇ m. If the inner diameter is smaller than this, when filtration is performed from the inside toward the outside, the pressure loss due to the liquid passage becomes large, and the filtration pressure may become non-uniform in the length direction of the hollow fiber membrane.
- a lumen in the liquid may be blocked due to components in the liquid to be processed. If the inner diameter is larger than this, the hollow fiber membrane is liable to be crushed or distorted. When the film thickness is smaller than this, the hollow fiber membrane tends to be crushed or distorted. When the film thickness is larger than this, the resistance when the liquid to be treated passes through the film wall increases, and the permeability may decrease.
- the bacteriophage clearance of the porous hollow fiber membrane for protein-containing liquid treatment of the present invention is preferably 4 or more and more preferably 5 or more as LRV. By having such characteristics, it can be preferably applied to virus removal from protein-containing liquids.
- the bacteriophage mentioned here is preferably a bacteriophage having a diameter of 20 to 30 nm such as PP7, ⁇ X174, and more preferably ⁇ X174 from the viewpoint of easy handling of host bacteria.
- the method for producing the porous protein fiber-containing porous hollow fiber membrane of the present invention is not limited in any way, but a hydrophobic polymer, a hydrophilic polymer, a solvent, and a non-solvent are mixed and dissolved, and defoamed.
- a film-forming solution the core solution is simultaneously discharged from the annular part and the center part of the double-tube nozzle and led to the coagulation bath through the idle running part (air gap part) to form a hollow fiber membrane (dry and wet spinning) Method), a method of winding and drying after washing with water.
- Solvents used in the film-forming solution were N-methyl-2-pyrrolidone (hereinafter abbreviated as NMP), N, N-dimethylformamide (hereinafter abbreviated as DMF), N, N-dimethylacetamide (hereinafter abbreviated as DMAc). ), Dimethyl sulfoxide (hereinafter abbreviated as DMSO), ⁇ -caprolactam, etc., can be widely used as long as it is a good solvent for hydrophobic polymers and hydrophilic polymers.
- NMP N-methyl-2-pyrrolidone
- DMF N-dimethylformamide
- DMAc N-dimethylacetamide
- DMSO Dimethyl sulfoxide
- ⁇ -caprolactam etc.
- the aprotic solvent means a hydrogen bonded directly to a hetero atom other than a carbon atom in the structure. It means a solvent containing no atoms.
- non-solvent examples include ethylene glycol (hereinafter abbreviated as EG), propylene glycol (hereinafter abbreviated as PG), diethylene glycol (hereinafter abbreviated as DEG), triethylene glycol (hereinafter abbreviated as TEG), Polyethylene glycol (hereinafter abbreviated as PEG), glycerin, water, etc.
- EG ethylene glycol
- PG propylene glycol
- DEG diethylene glycol
- TEG triethylene glycol
- PEG Polyethylene glycol
- glycerin glycerin, water, etc.
- the ether polyol means a substance having at least one ether bond and two or more hydroxyl groups in the structure.
- phase separation (coagulation) in the spinning process is controlled by using a membrane-forming solution prepared using these solvents and non-solvents, and the preferred membrane structure of the present invention is formed. It is thought that it becomes advantageous to do.
- the composition of the core liquid described later and the composition of the liquid in the coagulation bath (external coagulation liquid) are also important.
- the solvent / non-solvent ratio in the film forming solution is an important factor for controlling phase separation (coagulation) in the spinning process. It is preferable that the non-solvent is the same amount or slightly excess with respect to the solvent. Specifically, the solvent / non-solvent is preferably 25/75 to 50/50 by weight, and preferably 30/70 to 50/50. / 50 is more preferable, and 35/65 to 50/50 is even more preferable. If the content of the solvent is less than this, solidification tends to proceed, the membrane structure becomes too dense, and the permeability is lowered. On the other hand, if the solvent content is higher than this, the progress of the phase separation is excessively suppressed, and pores having a large pore diameter are likely to be generated, which increases the possibility of degrading the separation characteristics and strength.
- the concentration of the hydrophobic polymer in the film-forming solution is not particularly limited as long as film formation from the solution is possible, but is preferably 10 to 40% by weight, more preferably 10 to 30% by weight, and 15 to 25% by weight. Is more preferable.
- the concentration of the hydrophobic polymer is preferably low, but if it is too low, the strength may be reduced and the separation characteristics may be deteriorated, so 15 to 25% by weight is preferable.
- the amount of hydrophilic polymer added is sufficient to impart hydrophilicity to the hollow fiber membrane and prevent non-specific adsorption during filtration of the liquid to be processed, without affecting the membrane formation from the membrane-forming solution.
- the concentration of the hydrophilic polymer in the film forming solution is preferably 2 to 15% by weight, more preferably 2 to 10% by weight, and further preferably 3 to 8% by weight. If the amount of the hydrophilic polymer added is less than this, the imparting of hydrophilicity to the film will be insufficient, and the retention of film characteristics may be reduced. In addition, if it is more than this, the hydrophilicity imparting effect is saturated and the efficiency is not good, and the phase separation (coagulation) of the film forming solution is likely to proceed excessively, and the operability deteriorates, This is disadvantageous in forming the preferred membrane structure of the present invention.
- a film-forming solution can be obtained by mixing a hydrophobic polymer, a hydrophilic polymer, a solvent, and a non-solvent and dissolving them by stirring. At this time, the solution can be efficiently dissolved by appropriately applying a temperature. However, excessive heating may cause decomposition of the polymer, so that the temperature is preferably 30 to 100 ° C., more preferably 40 to 80 ° C. is there.
- PVP polymer
- the PVP tends to undergo oxidative decomposition due to the influence of oxygen in the air
- Eliminating bubbles from the membrane forming solution is effective for obtaining a hollow fiber membrane having no defects.
- As a method for suppressing the mixing of bubbles it is effective to defoam the film forming solution.
- static defoaming or vacuum defoaming can be used.
- the tank is sealed and allowed to stand for 30 to 180 minutes. This operation is repeated several times to perform a defoaming process. If the degree of vacuum is too low, the treatment may take a long time because it is necessary to increase the number of defoaming times.
- the total treatment time is preferably 5 minutes to 5 hours. If the treatment time is too long, the components of the film-forming solution may be decomposed and deteriorated due to the effect of reduced pressure. If the treatment time is too short, the defoaming effect may be insufficient. Further, a method can be adopted in which a depressurization portion is provided in a flow path for guiding the film forming solution from the tank to the nozzle, and defoaming is performed while the film forming solution is flowing. The degree of pressure reduction at this time is preferably from normal pressure to 0.005 to normal pressure to 0.030 MPa.
- a film-forming solution from which foreign matters are excluded in order to avoid generation of defects in the membrane structure due to foreign matters mixed into the hollow fiber membrane.
- a method of using a raw material with less foreign matter, filtering the film forming solution, and reducing foreign matter is effective.
- the uniformly-dissolved membrane-forming solution is discharged from the dissolution tank.
- a sintered filter having a pore diameter of 10 to 50 ⁇ m provided while being led to the nozzle is passed through. The filtration treatment may be performed at least once.
- the pore size of the filter is more preferably 10 to 45 ⁇ m, further preferably 10 to 40 ⁇ m. If the filter pore size is too small, the back pressure may increase and productivity may decrease.
- the composition of the core liquid used when forming the hollow fiber membrane is preferably a liquid mainly composed of a solvent and / or a non-solvent contained in the membrane forming solution.
- a preferable surface structure cannot be obtained with only the solvent contained in the film-forming solution because coagulation on the lumen wall surface is excessively suppressed. Therefore, it is preferable to use any of a mixed solution of a solvent and a non-solvent, a non-solvent alone, a mixed solution of a solvent and water, a mixed solution of a non-solvent and water, or a mixed solution of a solvent, a non-solvent, and water.
- the amount of the organic component contained in the core liquid is preferably 50 to 100% by weight, and more preferably 60 to 100% by weight. More specifically, when the core liquid is a mixture of a solvent and water, the amount of the organic component is 50 to 65% by weight. When the core liquid is a mixture of the non-solvent and water, the amount of the organic component is When the core solution is a mixed solution of solvent, non-solvent and water, the same solvent / non-solvent ratio as the film-forming solution is used, and this is diluted with water. It is preferable that the content be ⁇ 95% by weight. If the content of the organic component is less than this, solidification tends to proceed, the membrane structure becomes too dense, and the permeability decreases. On the other hand, if the content of the organic component is larger than this, the progress of phase separation is excessively suppressed, and pores having a large pore diameter are likely to be generated, which increases the possibility of degrading separation characteristics and strength.
- the composition of the external coagulation liquid is preferably a mixed liquid of a solvent and a non-solvent contained in the film forming solution and water.
- the ratio of the solvent and the non-solvent contained in the external coagulation liquid is the same as the solvent / non-solvent ratio of the film forming solution.
- the same solvent and non-solvent that are used for the film-forming solution are mixed in the same ratio as in the film-forming solution, and diluted by adding water to this is preferably used.
- the content of water in the external coagulation liquid is 20 to 70% by weight, preferably 30 to 60% by weight. If the water content is higher than this, solidification tends to proceed, the membrane structure becomes too dense, and the permeability decreases.
- one of the factors controlling the film structure is the temperature of the nozzle. If the temperature of the nozzle is low, solidification tends to proceed, the membrane structure becomes too dense, and the permeability decreases. On the other hand, if it is high, the progress of the phase separation is excessively suppressed, and pores having a large pore diameter are likely to be formed, and the possibility of causing a decrease in separation characteristics and strength is increased. It is.
- the membrane-forming solution discharged from the double tube nozzle together with the core solution is in a coagulation bath filled with an external coagulation solution through an air gap portion.
- a dry-wet spinning method in which a hollow fiber membrane is formed by guiding to the above is exemplified, but the residence time in the air gap portion of the membrane-forming solution discharged from the nozzle is one of the factors that control the membrane structure. If the residence time is short, the outer coagulating liquid quenches the growth of aggregated particles due to phase separation in the air gap portion, so that the outer surface becomes dense and the permeability is lowered.
- a preferable range of the residence time in the air gap is 0.01 to 2 seconds, more preferably 0.02 to 1 second, and further preferably 0.02 to 0.5 seconds.
- the draft ratio in the air gap part and the coagulation bath that is, the ratio between the take-up speed from the coagulation bath and the film-forming solution discharge line speed from the double-tube nozzle can control the fine membrane structure and pass through the hollow fiber membrane. It is one of the factors that control the characteristics.
- the draft ratio mentioned here may be considered exclusively as the stretch ratio in the air gap part, but the orientation of the polymer chains can be adjusted by applying appropriate stretching in the air gap where the growth of the aggregated particles due to phase separation is suppressed. It is believed that this will affect the microstructure of the film.
- the draft ratio is preferably 2 to 20, preferably 4 to 15.
- the draft ratio is smaller than this, the fall of the filtrate collection amount due to the filtration time tends to be large, and the removal effect of the substance to be removed such as viruses may not be sufficiently exerted. If the draft ratio is higher than this, yarn breakage is likely to occur and the operability may be lowered.
- the hollow fiber membrane led to the coagulation bath after being moderately stretched at the air gap part with a relatively short residence time is suppressed to some extent from the outside while coagulation from the core liquid proceeds.
- the residence time in the coagulation bath is important for the control of the film structure, and specifically, it is preferably 1 to 15 seconds, more preferably 2 to 10 seconds, and further preferably 2 to 5 seconds. If the residence time in the coagulation bath is shorter than this, coagulation is insufficient, and if it is longer than this, the film-forming speed is reduced and the coagulation bath needs to be enlarged.
- the hollow fiber membrane pulled up from the coagulation bath is guided to a washing bath filled with warm water and washed in a heated state, whereby a hollow fiber membrane having preferable separation characteristics, permeation characteristics, and a membrane structure can be obtained.
- a technique of intermittently immersing several times in the warm water in the washing bath by so-called Nelson roller running in which a constant speed roller provided at both ends of the washing bath is reciprocated several times, can be used.
- Nelson roller running the hollow fiber membrane is alternately contacted with hot water and air alternately, but the hollow fiber membrane shrinks slightly while being dried by air running, and the speed is controlled by a constant speed roller. Therefore, a subtle change in tension is given.
- the warm water contact by Nelson roller running is set to 5 to 15 times, preferably 8 to 12 times, and the total residence time in warm water is set to 15 to 60 seconds, preferably 20 to 45 seconds.
- the temperature of the hot water is preferably 30 to 100 ° C, more preferably 40 ° C to 90 ° C.
- the film forming speed is not particularly limited as long as a hollow fiber membrane having no defect can be obtained and productivity can be secured, but is preferably 5 to 40 m / min, more preferably 10 to 30 m / min. If the spinning speed is lower than this, productivity may be lowered. If the spinning speed is higher than this, it may be difficult to ensure the above spinning conditions, particularly the residence time in the air gap portion and the residence time in the coagulation bath.
- the hollow fiber membrane obtained through on-line cleaning after film formation suppresses changes in membrane properties during use and washing operations, and ensures the retention and stability of membrane properties and the recovery of membrane properties.
- Heat treatment is preferably performed. By making this heat treatment an immersion treatment in hot water, the effect of washing and removing the solvent, non-solvent, etc. remaining in the hollow fiber membrane can be expected at the same time.
- a technique of aging by immersing the hollow fiber membrane in a solvent / non-solvent aqueous solution is used prior to the immersion treatment in hot water. Can be done. By performing this aging, it is considered that the content and existence state of the hydrophilic polymer in the film are optimized, and the permeation characteristics are optimized.
- the immersion liquid in this step is preferably the same as the solvent / non-solvent ratio of the film-forming solution and then diluted with water to make the organic component concentration 10 to 60% by weight.
- the immersion treatment temperature is preferably 15 to 30 ° C. and the immersion time is preferably 10 to 180 minutes. If the organic component concentration is lower than this, if the temperature is low, or if the time is short, excess hydrophilic polymer tends to remain, and the liquid to be treated due to changes in membrane characteristics over time and elution during actual use May cause problems such as contamination. If the organic component concentration is higher than this, if the temperature is high, or if the time is long, the separation characteristics and strength may be reduced due to destruction of the lumen surface structure, excessive extraction of hydrophilic polymer, etc. There is.
- the temperature of the hot water used for the heat treatment of the hollow fiber membrane subjected to the aging is 40 to 100 ° C., more preferably 60 to 95 ° C., the treatment time is 30 to 90 minutes, more preferably 40 to 80 minutes, Preferably it is 50 to 70 minutes. If the temperature is lower than this and the processing time is shorter than this, the heat history applied to the hollow fiber membrane may be insufficient, and the retention and stability of the membrane characteristics may be lowered, and the cleaning effect is insufficient. Therefore, there is a high possibility that the amount of eluate increases. If the temperature is higher than this and the treatment time is longer than this, the water may boil or the treatment may take a long time, resulting in a decrease in productivity.
- the bath ratio of the hollow fiber membrane to hot water is not particularly limited as long as the hollow fiber membrane is sufficiently immersed in the hot water, but using too much hot water may reduce productivity. There is. Also, during this heat treatment, if the hollow fiber membrane is bundled in an appropriate length and immersed in hot water in an upright state, the hot water can easily reach the lumen part, and the viewpoint of the heat treatment / cleaning effect To preferred.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention is preferably treated with high-pressure hot water immediately after the above heat treatment. Specifically, it is preferably set in a high-pressure steam sterilizer in a submerged state and processed at a processing temperature of 120 to 140 ° C. and a processing time of 20 to 120 minutes, which are normal high pressure steam sterilization conditions. At this time, it is preferable that the hollow fiber membrane which has been subjected to the heat treatment is immediately started to be subjected to the high-pressure hot water treatment in a wet state and in a high temperature state.
- heat treatment raises the temperature of the membrane and further “high pressure” hydrothermal treatment in a “relaxed” state optimizes the presence state at the same time as removing excess hydrophilic polymer. It is considered that the transmission characteristics are optimized. If the treatment temperature is lower than the above range, or if the treatment time is short, the treatment conditions are too mild to remove excess hydrophilic polymer and to optimize the existence state, resulting in changes in membrane characteristics over time. There is a greater possibility of causing problems such as contamination of the liquid to be treated due to elution during use. When the processing temperature is higher than the above range, when the processing time is long, the processing conditions are harsh, leading to degradation of separation characteristics and strength due to destruction of the membrane structure, excessive extraction of hydrophilic polymer, etc. there is a possibility.
- an additive may be added to the immersion liquid used for the high-pressure hot water treatment.
- the additive is preferably a substance having an antioxidant effect and a radical trap effect, such as sulfite and polyhydric alcohol.
- sulfite and polyhydric alcohol a radical trap effect
- the amount of addition varies depending on the type of additive, but in the case of sulfite, it is 0.01 to 1%, preferably 0.01 to 0.1%, and in the case of polyhydric alcohol, it is 0.1 to 20%, preferably 1 to 10%.
- the above-mentioned hot water treatment may be performed once more to remove the additive by washing.
- the hollow fiber membrane that has been subjected to membrane formation, heat treatment, and high-pressure hydrothermal treatment is finally completed by drying.
- drying methods such as air drying, reduced pressure drying, hot air drying, and microwave drying can be widely used.
- microwave drying recently used for drying blood treatment membranes can be preferably used in that a large amount of hollow fiber membranes can be efficiently dried at a relatively low temperature.
- the drying temperature is room temperature to 70 ° C, preferably 30 to 65 ° C. If the temperature is lower than this, it takes a long time to dry, and if the temperature is higher than this, the energy cost for generating hot air becomes high, which is not preferable.
- the moisture content after the drying treatment is preferably 1 It is preferable to set it to ⁇ 8%, more preferably 2 to 6%. If the moisture content is lower than this, it is difficult to obtain preferable permeation characteristics. If the moisture content is higher than this, the moisture content increases and the handleability may deteriorate.
- a hollow fiber membrane bundle was produced by cutting a hollow fiber membrane into a length of about 30 cm and bundling both ends with a paraffin film. Both ends of this hollow fiber membrane bundle were inserted into a pipe (sleeve) and hardened with a urethane potting agent. The ends were cut to obtain a double-end open mini-module with both ends fixed by sleeves. The number of hollow fiber membranes was appropriately set so that the surface area of the inner surface was 30 to 50 cm 2 .
- the membrane area of the module was determined based on the inner diameter of the hollow fiber membrane.
- the membrane area A [m 2 ] of the module can be calculated by the following equation [2].
- A n ⁇ ⁇ ⁇ d ⁇ L [2]
- n is the number of hollow fiber membranes
- ⁇ is the circumference
- d is the inner diameter [m] of the hollow fiber membrane
- L is the effective length [m] of the hollow fiber membrane in the module.
- a circuit is connected to two end sleeves of the mini module (referred to as lumen inlet and lumen outlet, respectively), and the inflow pressure of liquid to the mini module and the outflow pressure of liquid from the mini module Can be measured.
- the circuit (downstream from the pressure measurement point) connected to the inner surface outlet was sealed with forceps to stop the flow, and the pure water entered from the lumen inlet of the module was totally filtered.
- Circuits were connected to the two end tips (referred to as the lumen inlet and the lumen outlet, respectively) of the mini-module with an outer cylinder to enable liquid introduction into and out of the hollow fiber membrane lumen.
- the liquid inlet pressure can be measured on the liquid inlet side.
- the liquid outlet side was sealed with forceps to stop the flow, and the total amount of liquid entered from the lumen inlet of the module was filtered.
- IVIG / PBS was placed in a pressurized tank and kept at 25 ° C., and the pressure was controlled with a regulator so that the filtration pressure would be 1.0 bar, and the IVIG / PBS was introduced into the lumen of the mini module with an outer cylinder.
- the filtrate obtained from the outer surface of the hollow fiber membrane was collected from the side tube of the chip.
- the filtrate was received by changing the container at each time point (5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes from the start of filtration). .
- the filtrate collection amount of each fraction was read from the value displayed on the electronic balance.
- Throughput TPn [L / m 2 ] up to the time point Tn was calculated by the following equation [5].
- TPn Wn ⁇ 1.0 ⁇ A ⁇ 1000 [5]
- W is the total amount of filtrate collected up to the fraction at the time of starting filtration n minutes [g]
- 1.0 is the density [g / cc] of IVIG / PBS
- A is the membrane area [m 2 ] of the module.
- the immunoglobulin permeability P was calculated by the following equation [6] from the filtrate of each fraction obtained in the filtration test and IVIG / PBS as the filtrate.
- P 100 [%] x (protein concentration in the filtrate) / (protein concentration in the filtrate IVIG / PBS) [6]
- the protein concentration of the filtrate IVIG / PBS and the protein concentration in the filtrate were determined by measuring the absorbance at 280 nm and calculating the concentration from a calibration curve prepared with an immunoglobulin solution having a known concentration.
- E. coli solution Phage titration measurement of test phage solution and filtrate E. coli was suspended in 10 mM MgSO 4 aqueous solution so that the absorbance at 660 nm was 4.0 (hereinafter referred to as E. coli solution) .
- E. coli solution 10 mM MgSO 4 aqueous solution so that the absorbance at 660 nm was 4.0
- an agar medium and top agar were prepared and warmed to 50 ° C. in advance. Especially the top agar was careful to keep the fluidity. 10 ⁇ L of a solution obtained by appropriately diluting the test phage solution with a BSA solution and 50 ⁇ L of E. coli solution were mixed, and incubated at 37 ° C. for 20 minutes to infect phages in E. coli.
- the total amount of this mixed solution was mixed with 3 mL of top agar, and the entire amount was rapidly spread on an agar medium. After the top agar was completely solidified on the agar medium, it was incubated at 37 ° C. for 2 to 4 hours. After completion of the incubation, the number of plaques on the agar medium was counted, and the titer of the test phage solution (hereinafter abbreviated as Tpre) [pfu / mL] was calculated in consideration of the dilution rate.
- Tpre titer of the test phage solution
- phage clearance index of hollow fiber membrane was calculated by the following formula [7].
- Tpre [pfu / mL] is the titer of the test phage solution introduced into the evaluation hollow fiber membrane
- Tpost [pfu / mL] is the test phage solution filtered through the evaluation hollow fiber membrane. It is a phage titer of the obtained filtrate.
- Phage clearance index [LRV] log 10 (Tpre / Tpost) [7]
- Example 1 PES (BASF Ultrason (trade name) E6020P) 20 parts by weight, BASF PVP (Luvitec (trade name) K90PH) 6 parts by weight, Mitsubishi Chemical NMP 33.3 parts by weight, Mitsui Chemicals TEG 40.7 parts by weight The parts were mixed and dissolved at 55 ° C. for 6 hours to obtain a uniform solution. At this time, the inside of the system was repeatedly purged with nitrogen several times by reducing pressure and introducing nitrogen, and a solution was prepared in a sealed state. After preparing the solution, the pressure was reduced to normal pressure -0.09 MPa at 55 ° C., and the system was immediately sealed and left for 30 minutes so that the solvent composition would not volatilize and change the solution composition.
- BASF Ultrason (trade name) E6020P 20 parts by weight
- BASF PVP Livitec (trade name) K90PH
- Mitsubishi Chemical NMP 33.3 parts by weight Mitsubishi Chemical NMP 33.3 parts by weight
- Mitsui Chemicals TEG 40.7 parts by weight The
- the solution was continuously defoamed in a reduced pressure portion provided in a flow path connecting the tank to the nozzle, and then introduced into the nozzle.
- the temperature of the flow path was 55 ° C.
- the degree of pressure reduction in the reduced pressure portion was normal pressure ⁇ 0.015 MPa.
- the above film-forming solution is discharged from the annular part of the double-tube nozzle, and a mixed liquid of NMP 38.25 parts by weight, TEG 46.75 parts by weight and RO water 15 parts by weight is discharged from the center part as a core liquid, through a 15 mm air gap. Then, it was led to a coagulation bath filled with an external coagulation liquid consisting of a mixed liquid of 27 parts by weight of NMP, 33 parts by weight of TEG, and 40 parts by weight of RO water. At this time, the nozzle temperature was set to 55 ° C., and the external coagulating liquid temperature was set to 60 ° C. The hollow fiber membrane pulled up from the coagulation bath was guided to a washing tank filled with 55 ° C. warm water, and was run 10 times with Nelson roller, then pulled out and wound up by a winder.
- the spinning speed was 22.2 m / min
- the running length of the hollow fiber membrane in the coagulation bath was 900 mm
- the residence time in the coagulation bath was 2.43 seconds.
- the running length was set so that the residence time in the washing tank was 30 seconds.
- the hollow fiber membrane was controlled in terms of the amount of membrane-forming solution and core liquid discharged so that the inner diameter was about 200 ⁇ m and the film thickness was about 60 ⁇ m.
- the air gap retention time of the hollow fiber membrane calculated from the above conditions was 0.04 seconds.
- the draft ratio was 10.5.
- the wound hollow fiber membranes were bundled in 2280 bundles with a length of 35 cm. After removing the core liquid, the mixture was immediately added to a mixed solution of 22.5 parts by weight of NMP, 27.5 parts by weight of TEG, and 50 parts by weight of RO water. Immersion at 60 ° C for 60 minutes. Thereafter, the immersion liquid was removed, and the hot water treatment was performed by immersing in RO water at 80 ° C. for 60 minutes in an upright state. The hollow fiber membrane that had been subjected to the heat treatment was immediately immersed in a high-pressure steam sterilizer containing hot water at 40 ° C. in a wet state, and was subjected to high-pressure hot water treatment under conditions of 132 ° C. ⁇ 20 minutes.
- glycerin was added to the hot water to a concentration of 1% by weight.
- the high-pressure hot water treatment was performed once again under the conditions described above.
- hollow fiber membrane bundles of 12 are placed on two rotary tables and placed in a microwave dryer, irradiated with 1.5kW of microwaves, and the interior of the dryer is reduced to 7 kPa and dried for 36 minutes. It was. Subsequently, drying was performed for 18 minutes under a reduced pressure of 7 kPa by setting the microwave output, and the microwave output was further reduced to 0.4 kW to complete the drying for 8 minutes.
- the highest temperature reached on the surface of the hollow fiber membrane in the drying step was 60 ° C., and the moisture content of the dried hollow fiber membrane was 3.3%.
- the central region of the film thickness portion of the hollow fiber membrane (A) had a substantially homogeneous structure, and the film thickness portion did not have macrovoids.
- the pure water flux of the hollow fiber membrane (A) was measured by the method described above, and an immunoglobulin permeation test was performed. From the obtained data, the relationship between immunoglobulin filtration time and throughput was analyzed by the method described above. The characteristics and properties of these hollow fiber membranes (A) are summarized in Table 1. The relationship between immunoglobulin filtration time and throughput is shown in FIG.
- the hollow fiber membrane (hereinafter abbreviated as? X174-CL50) area 1m 2 per filtration load 50L point of reduction factor of bacteriophage? X174 and hollow fiber membrane area 1m per 2 filtration load of 200L time
- the clearance index of bacteriophage ⁇ X174 (hereinafter abbreviated as ⁇ X174-CL200) was measured. The results are summarized in Table 1.
- Example 2 A hollow fiber membrane (B) was obtained in the same manner as in Example 1 except that the drying method was changed.
- the hollow fiber membrane (B) was obtained by drying by the following method. Twenty-four hollow fiber membrane bundles that had been subjected to high-pressure hot water treatment were placed on a shelf board and dried by passing hot air at 60 ° C. for 6 hours. The maximum temperature reached on the surface of the hollow fiber membrane in the drying step was 60 ° C., and the moisture content of the dry hollow fiber membrane was 2.4%.
- the characteristics and properties of the hollow fiber membrane (B), P5 and P60, ⁇ X174-CL50 and ⁇ X174-CL200 measured in the same manner as in Example 1, are shown in Table 1. The relationship between immunoglobulin filtration time and throughput is shown in FIG.
- Example 3 A hollow fiber membrane (C) was obtained in the same manner as in Example 1 except that the draft ratio was changed to 4.2.
- the highest temperature reached on the surface of the hollow fiber membrane in the drying step was 60 ° C., and the moisture content of the dried hollow fiber membrane was 3.1%.
- the characteristics and properties of the hollow fiber membrane (C), P5 and P60, ⁇ X174-CL50 and ⁇ X174-CL200 measured in the same manner as in Example 1, are shown in Table 1.
- the relationship between immunoglobulin filtration time and throughput is shown in FIG.
- Example 4 The composition of the film-forming solution was 19 parts by weight of PES (BASF Ultrason (trade name) E6020P), 6 parts by weight of BASF PVP (Luvitec (trade name) K90PH), Mitsubishi Chemical NMP 33.75 parts by weight, Mitsui Chemicals TEG 41.25 parts by weight, nozzle temperature 53 ° C, external coagulation liquid composition NMP 18 parts by weight, TEG 22 parts by weight, RO water 60 parts by weight, external coagulation liquid temperature 50 ° C, air
- a hollow fiber membrane (D) was obtained in the same manner as in Example 1 except that the gap length was 30 mm and the air gap retention time of the hollow fiber membrane was set to 0.08 seconds.
- the highest temperature reached on the hollow fiber membrane surface in the drying step was 60 ° C., and the moisture content of the dried hollow fiber membrane was 3.6%.
- the characteristics and properties of the hollow fiber membrane (D), P5 and P60, ⁇ X174-CL50 and ⁇ X174-CL200 measured in the same manner as in Example 1 are shown in Table 1.
- the relationship between immunoglobulin filtration time and throughput is shown in FIG.
- Example 5 The composition of the film-forming solution is 20 parts by weight of PES (Sumitomo Chemtech Co., Ltd., Sumika Excel (trade name) 5200P), 6 parts by weight of BASF PVP (Luvitec (trade name) K90PH), NMP 33.3 parts by weight of Mitsubishi Chemical Corporation, Example 1 except that Mitsui Chemicals made TEG 40.7 parts by weight, nozzle temperature was 53 ° C, and the composition of the external coagulation liquid was NMP 18 parts by weight, TEG 22 parts by weight, RO water 60 parts by weight. Thus, a hollow fiber membrane (E) was obtained.
- PES Suditomo Chemtech Co., Ltd., Sumika Excel (trade name) 5200P)
- BASF PVP Livitec (trade name) K90PH
- NMP 33.3 parts by weight of Mitsubishi Chemical Corporation Example 1 except that Mitsui Chemicals made TEG 40.7 parts by weight, nozzle temperature was 53 ° C, and the composition of the external coagulation liquid was NMP 18 parts by
- the highest temperature reached on the surface of the hollow fiber membrane in the drying step was 60 ° C., and the moisture content of the dried hollow fiber membrane was 2.9%.
- the characteristics and properties of the hollow fiber membrane (E), P5 and P60, ⁇ X174-CL50 and ⁇ X174-CL200 measured in the same manner as in Example 1 are shown in Table 1.
- the relationship between immunoglobulin filtration time and throughput is shown in FIG.
- Example 6 PSf (Amoco P-3500) 20 parts by weight, BASF PVP (Luvitec (trade name) K90PH) 6 parts by weight, Mitsubishi Chemical NMP 33.3 parts by weight, Mitsui Chemicals TEG40 A hollow fiber membrane (same as in Example 1) except that the composition was 0.7 parts by weight, the nozzle temperature was 56 ° C., and the external coagulation liquid was composed of 18 parts by weight of NMP, 22 parts by weight of TEG, and 60 parts by weight of RO water. F) was obtained. The highest temperature reached on the hollow fiber membrane surface in the drying step was 60 ° C., and the moisture content of the dried hollow fiber membrane was 3.6%.
- Example 7 PES (BASF Ultrason (trade name) E6020P) 20 parts by weight, BASF PVP (Luvitec (trade name) K90PH) 6 parts by weight, Mitsubishi Chemical NMP 33.3 parts by weight, Mitsui Chemicals TEG 40.7 parts by weight The parts were mixed and dissolved at 55 ° C. for 6 hours to obtain a uniform solution. At this time, the inside of the system was repeatedly purged with nitrogen several times by reducing pressure and introducing nitrogen, and a solution was prepared in a sealed state. After preparing the solution, the pressure was reduced to normal pressure -0.09 MPa at 55 ° C., and the system was immediately sealed and left for 30 minutes so that the solvent composition would not volatilize and change the solution composition.
- BASF Ultrason (trade name) E6020P) 20 parts by weight, BASF PVP (Luvitec (trade name) K90PH) 6 parts by weight, Mitsubishi Chemical NMP 33.3 parts by weight, Mitsui Chemicals TEG 40.7 parts by weight The parts were mixed and
- the solution was continuously defoamed in a reduced pressure portion provided in a flow path connecting the tank to the nozzle, and then introduced into the nozzle.
- the temperature of the flow path was 55 ° C.
- the degree of pressure reduction in the reduced pressure portion was normal pressure ⁇ 0.015 MPa.
- the above film-forming solution is discharged from the annular part of the double-tube nozzle, and a mixed liquid of NMP 38.25 parts by weight, TEG 46.75 parts by weight and RO water 15 parts by weight is discharged from the center part as a core liquid, through a 15 mm air gap. Then, it was led to a coagulation bath filled with an external coagulation liquid consisting of a mixed liquid of 27 parts by weight of NMP, 33 parts by weight of TEG, and 40 parts by weight of RO water. At this time, the nozzle temperature was set to 55 ° C., and the external coagulating liquid temperature was set to 60 ° C. The hollow fiber membrane pulled up from the coagulation bath was run once in a washing tank filled with hot water at 55 ° C. and then pulled out and wound up by a winder.
- the spinning speed was 22.2 m / min
- the running length of the hollow fiber membrane in the coagulation bath was 900 mm
- the residence time in the coagulation bath was 2.43 seconds.
- the running length was set so that the residence time in the washing tank was 11 seconds.
- the hollow fiber membrane was controlled in terms of the amount of membrane-forming solution and core liquid discharged so that the inner diameter was about 200 ⁇ m and the film thickness was about 60 ⁇ m.
- the air gap retention time of the hollow fiber membrane calculated from the above conditions was 0.04 seconds.
- the draft ratio was 10.5.
- the wound hollow fiber membranes were bundled into 2280 bundles with a length of 35 cm, and after removing the core liquid, they were immersed in 80 ° C. RO water for 60 minutes in an upright state and subjected to hot water treatment.
- the hollow fiber membrane that had been subjected to the heat treatment was immediately immersed in a high-pressure steam sterilizer containing hot water at 40 ° C. in a wet state, and was subjected to high-pressure hot water treatment under conditions of 132 ° C. ⁇ 20 minutes.
- the hollow fiber membrane is submerged in a high-pressure steam sterilizer containing hot water at 40 ° C in a wet state, and once again under high pressure at 134 ° C for 20 minutes. Hot water treatment was performed.
- hollow fiber membrane bundles of 12 are placed on two rotary tables and placed in a microwave dryer, irradiated with 1.5kW of microwaves, and the interior of the dryer is reduced to 7 kPa and dried for 36 minutes. It was. Subsequently, drying was performed for 18 minutes under a reduced pressure of 7 kPa by setting the microwave output, and the microwave output was further reduced to 0.4 kW to complete the drying for 8 minutes.
- the maximum temperature reached on the surface of the hollow fiber membrane in the drying step was 60 ° C., and the moisture content of the dry hollow fiber membrane was 3.2%.
- the highest temperature reached on the surface of the hollow fiber membrane in the drying step was 60 ° C., and the moisture content of the dry hollow fiber membrane was 3.0%.
- the characteristics and properties of the hollow fiber membrane (I), P5 and P60, ⁇ X174-CL50 and ⁇ X174-CL200 measured in the same manner as in Example 1 are shown in Table 2.
- the relationship between immunoglobulin filtration time and throughput is shown in FIG.
- a hollow fiber membrane (J) was obtained in the same manner as in Example 1 except that glycerin was not added to the first high-pressure hot water treatment immersion liquid and the drying method was changed.
- the hollow fiber membrane (J) was obtained by drying by the following method. Twenty-four hollow fiber membrane bundles that had been subjected to high-pressure hot water treatment were placed on a shelf board and dried by passing hot air at 80 ° C. for 20 hours. The maximum temperature reached on the surface of the hollow fiber membrane in the drying step was 80 ° C., and the moisture content of the dry hollow fiber membrane was 0.2%.
- the solution was continuously defoamed in a reduced pressure portion provided in a flow path connecting the tank to the nozzle, and then introduced into the nozzle.
- the temperature of the flow path was 55 ° C.
- the degree of pressure reduction in the reduced pressure portion was normal pressure ⁇ 0.015 MPa.
- the film-forming solution is discharged from the annular part of the double-tube nozzle, and a mixed liquid of NMP 38.25 parts by weight, TEG 46.75 parts by weight, and RO water 15 parts by weight is discharged from the center part as a core liquid, through a 20 mm air gap.
- NMP 26.1 parts by weight, TEG 31.9 parts by weight, RO water 42 parts by weight led to a coagulation bath filled with an external coagulation liquid.
- the nozzle temperature was set to 55 ° C.
- the external coagulation liquid temperature was set to 55 ° C.
- the hollow fiber membrane pulled up from the coagulation bath was led to a washing tank filled with hot water at 55 ° C., and the washing tank was run once without running the Nelson roller, and then pulled out and wound up by a winder.
- the spinning speed was 18.0 m / min
- the running length of the hollow fiber membrane in the coagulation bath was 2000 mm
- the residence time in the coagulation bath was 6.67 seconds.
- the running length was set so that the residence time in the washing tank was 11 seconds.
- the hollow fiber membrane was controlled in terms of the amount of the membrane-forming solution and core solution discharged so that the inner diameter was about 280 ⁇ m and the film thickness was about 80 ⁇ m.
- the air gap residence time of the hollow fiber membrane calculated from the above conditions was 0.05 seconds.
- the draft ratio was 2.0.
- the wound hollow fiber membranes were bundled into 2280 bundles with a length of 35 cm and aged by leaving at 25 ° C. for 60 minutes without removing the core liquid. Thereafter, the immersion liquid was removed, and the hot water treatment was performed by immersing in RO water at 85 ° C. for 60 minutes in an upright state.
- the hollow fiber membrane that had been subjected to the heat treatment was immediately immersed in a high-pressure steam sterilizer containing hot water at 40 ° C. in a wet state, and was subjected to high-pressure hot water treatment under conditions of 132 ° C. ⁇ 20 minutes.
- the 24 hollow fiber membrane bundles that had been subjected to the high-pressure hot water treatment were placed on a shelf board, and dried by passing hot air at 60 ° C. for 16 hours.
- the maximum temperature reached on the surface of the hollow fiber membrane in the drying step was 60 ° C., and the moisture content of the dry hollow fiber membrane was 1.8%.
- a hollow fiber membrane (K) having an inner diameter of 198 ⁇ m and a film thickness of 59 ⁇ m was obtained.
- the characteristics and properties of the hollow fiber membrane (K), P5 and P60, ⁇ X174-CL50 and ⁇ X174-CL200 measured in the same manner as in Example 1, are shown in Table 2.
- the relationship between immunoglobulin filtration time and throughput is shown in FIG.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention has no protein. It turns out that it permeate
- ⁇ X174 phage clearance index ( ⁇ X174-CL50) at filtration load 50L / m 2 and ⁇ X174 phage clearance index ( ⁇ X174-CL200) at filtration load 200L / m 2 not only at low filtration load Good bacteriophage removal performance is exhibited even under high filtration load.
- the separation of virus (or bacteriophage) by a porous membrane is considered to be contributed not only by size separation but also by some kind of interaction between the membrane surface and the virus, unlike ordinary separation membranes. It is considered that the membrane that clogs with time when the protein solution is filtered does not sufficiently suppress the interaction with the protein. In such a membrane, when a virus (or bacteriophage) -containing liquid is filtered, coexisting proteins interact with the membrane surface, inhibiting the interaction between the virus (or bacteriophage) and the membrane surface, resulting in clogging. It seems that a seemingly contradictory phenomenon occurs in which a leak of a virus (or bacteriophage) occurs in a membrane that is easy to progress.
- the porous hollow fiber membrane for protein-containing liquid treatment of the present invention can efficiently separate and remove removal substances such as small-diameter viruses contained in the solution, and at the same time, useful recovery substances such as proteins can efficiently permeate, It has the advantage that the permeation characteristic is less reduced over time, and is particularly useful for removing viruses from protein solutions, and greatly contributes to the industry.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Artificial Filaments (AREA)
- Spinning Methods And Devices For Manufacturing Artificial Fibers (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Abstract
Description
ウィルスクリアランス指数R = log ((V1× T1)/(V2×T2))
V1 工程処理前の容量 T1 工程処理前のウィルス力価
V2 工程処理後の容量 T2 工程処理後のウィルス力価
(1)最大孔径10~100nm
(2)グロブリン透過速度A>0.0015×最大孔径(nm)2.75
(3)グロブリン透過速度B/グロブリン透過速度A>0.2
(1) 疎水性高分子と親水性高分子を含んでなり、純水の透過速度が10~300L/(h・m2・bar)であり、0.5%免疫グロブリン溶液をデッドエンドで60分にわたり1.0barの定圧濾過した時、濾過時間と濾液回収積算量が実質的に直線関係にあることを特徴とする。
(2) 膜厚部分の中心領域が実質的に均質な構造からなり、かつ膜厚部分がマクロボイドを持たない構造からなることを特徴とする。
(3) 内径が150~400μm、膜厚が40~200μmであることを特徴とする。
(4) 疎水性高分子がポリスルホン系高分子であることを特徴とする。
(5) 親水性高分子がポリビニルピロリドンであることを特徴とする。
(6) タンパク質溶液からウィルスを分離するために使用される膜であることを特徴とする。
本発明のタンパク質含有液処理用多孔質中空糸膜は、疎水性高分子と親水性高分子を含んでなることが好ましい。疎水性高分子としては、例えば、ポリエステル、ポリカーボネート、ポリウレタン、ポリアミド、ポリスルホン(以下PSfと略記する)、ポリエーテルスルホン(以下PESと略記する)、ポリメチルメタクリレート、ポリプロピレン、ポリエチレン、PVDFなどが例示される。中でも、下記の化1、化2で示される繰返し単位を有するPSf、PESなどのポリスルホン系高分子は高い透水性の膜を得るのに有利であり、好ましい。ここで言うポリスルホン系高分子は、官能基やアルキル基などの置換基を含んでいてもよく、炭化水素骨格の水素原子はハロゲンなど他の原子や置換基で置換されていてもよい。また、これらは単独で使用しても、2種以上を混合して使用してもよい。
(1)IVIGをPBSで0.5%となるよう希釈し、pHを6.8に調整する。
(2)乾燥状態の中空糸膜にこの溶液を導入し、1.0barの濾過圧で、60分にわたって定圧濾過する。
(3)濾過開始から終了まで、ほぼ等間隔に(たとえば、濾過開始から5分、10分、20分、30分、40分、50分、60分)で濾過時間、濾液回収量を記録する。
(4)濾液回収量を膜面積で除して、スループットを算出する。
(5)濾過時間、スループットの数値をパソコン上の表計算ソフトに入力し、R2を算出する。
紡糸・後処理によって得られた中空糸膜バンドルを使用して、中空糸膜水分率を次式[1]により算出した。
中空糸膜水分率[%] = 100×(W1 + W2) / W1 [1]
ここで、W1は紡糸・後処理によって得られた中空糸膜バンドルの重量(g)、W2はこの中空糸膜バンドルを、120℃の乾熱オーブンで2時間にわたって乾燥した絶乾状態の中空糸膜バンドルの重量(g)である。
中空糸膜を約30cmの長さに切断し、両末端をパラフィンフィルムで束ねて中空糸膜束を作製した。この中空糸膜束の両端をパイプ(スリーブ)に挿入し、ウレタンポッティング剤で固めた。端部を切断して、両末端がスリーブで固定された両端開口ミニモジュールを得た。中空糸膜の本数は、内面の表面積が30~50cm2になるよう適宜設定した。
ポリ塩化ビニル製チューブ(約15cm長)の一方の端部に円筒状チップを、他方の端部に側管つき円筒状チップを装着した。この、両端にチップのついたポリ塩化ビニル製チューブに、約15cmの長さに切断した中空糸膜1本から5本を挿入し、中空糸膜内腔を塞がないように両端のチップ部分をシリコーン接着剤で固めた。この外筒つきミニモジュールは、端部のチップ部分から中空糸膜内腔へ液を導入することで中空糸膜の内腔から外壁方向への濾過(内-外濾過)ができる上、側管から液を導入することで外壁から内腔方向への濾過(外-内濾過)を行うこともできる。
モジュールの膜面積は中空糸膜の内面側の径を基準として求めた。次式[2]によってモジュールの膜面積A[m2]が計算できる。
A = n×π×d×L [2]
ここで、nは中空糸膜の本数、πは円周率、dは中空糸膜の内径[m]、Lはモジュールにおける中空糸膜の有効長[m]である。
ミニモジュールの末端スリーブ2箇所(それぞれ内腔流入口、内腔流出口と呼称する)に回路を接続し、ミニモジュールへの液体の流入圧とミニモジュールからの液体の流出圧を測定できるようにした。純水を加圧タンクに入れて25℃に保温し、濾過圧が1.0bar程度になるようレギュレーターで圧力を制御しながら、ミニモジュールの内腔流入口に純水を導入して中空糸膜の内腔に純水を満たした。内面流出口に接続した回路(圧力測定点よりも下流)を鉗子で封じて流れを止め、モジュールの内腔流入口から入った純水を全濾過するようにした。引き続きミニモジュールへ純水を送り、30秒にわたって濾過を行い、膜の馴化を行った。馴化処理中の濾液は廃棄した。その後、中空糸膜外面から得られる濾液量を2分間にわたって回収し、その量を測定した。また、濾過実施時の内腔流入口側圧力Pi、内腔流出口側圧力Poを測定し、次式[3]で膜間圧力差(TMP)ΔPを得た。
ΔP = (Pi + Po) / 2 [3]
濾過時間t[h] 、TMPΔP[bar]、ミニモジュールの膜面積A[m2]、濾液量V[L]から次式[4]により純水Flux[L/(h・m2・bar)]を得た。
純水Flux = V ÷ t ÷ A ÷ ΔP [4]
日水製薬(株)社から市販されているダルベッコPBS(-)粉末「ニッスイ」9.6gを蒸留水に溶解して全量を1000mLとし、PBSを得た。この緩衝液で、田辺三菱製薬(株)社から市販されている献血ヴェノグロブリン-IHヨシトミを希釈し、1mol/Lの水酸化ナトリウム水溶液でpHが6.8になるよう調整した。希釈、pH調整後の免疫グロブリン濃度は0.5%になるように調整した(以下この溶液をIVIG/PBSと略記する)。外筒つきミニモジュールの末端チップ2箇所(それぞれ内腔流入口、内腔流出口と呼称する)に回路を接続し、中空糸膜内腔への液導入出を可能にした。液導入側には液の流入圧を測定できるようにした。液導出側は鉗子で封じて流れを止め、モジュールの内腔流入口から入った液が全量濾過されるようにした。IVIG/PBSを加圧タンクに入れて25℃に保温し、濾過圧が1.0barになるようレギュレーターで圧力を制御しながら、外筒つきミニモジュールの内腔に導入した。中空糸膜外面から得られる濾過液は、チップの側管から回収した。濾液は、濾過開始から5分、10分、20分、30分、40分、50分、60分の各時点(濾過開始からn分の時点をTnと呼称する)で容器を換えて受けた。この際、各画分の濾液回収量は、電子天秤に表示された値から読み取った。Tn時点までのスループットTPn[L/m2]は、次式[5]で算出した。
TPn = Wn÷1.0÷A÷1000 [5]
ここで、Wは濾過開始n分時点の画分までの濾液回収量の総計[g]、1.0はIVIG/PBSの密度[g/cc]、Aはモジュールの膜面積[m2]である。
上記の濾過試験で得た濾過時間Tn、その濾過時間の時点までのスループットTPnの数値を、パソコン上の表計算ソフト(マイクロソフト・エクセル)に入力し、R2を算出した。
上記濾過試験で得た各画分の濾液、および被濾過液であるIVIG/PBSから、次式[6]で免疫グロブリン透過率Pを算出した。
P = 100[%]×(濾液中のタンパク濃度)/(被濾過液IVIG/PBSのタンパク濃度) [6]
ここで、被濾過液IVIG/PBSのタンパク濃度および濾液中のタンパク濃度は280nmの吸光度を測定し、既知濃度の免疫グロブリン溶液で作成した検量線から濃度を算出した。
(1)試験用ファージ液の調製
既述の手法で調製したPBSで、シグマアルドリッチジャパン(株)社から市販されている Albumin from bovine serum (製品番号A2153)を、0.1重量%となるよう溶解して0.1重量% BSA溶液(以下単にBSA溶液と呼称する)を得た。凍結保存した濃厚なφX174含有液(力価1~10×109pfu/mL)を解凍し、このBSA溶液で100倍に希釈した。さらに、0.1μm孔径のメンブレンフィルターで濾過、凝集成分などを除去して試験用ファージ液とした。
外筒つきミニモジュールの末端チップ2箇所(それぞれ内腔流入口、内腔流出口と呼称する)に回路を接続し、中空糸膜内腔への液導入出を可能にした。液導入側には液の流入圧を測定できるようにした。液導出側は鉗子で封じて流れを止め、モジュールの内腔流入口から入った液が全量濾過されるようにした。試験用ファージ液を加圧タンクに入れて25℃に保温し、濾過圧が1.0barになるようレギュレーターで圧力を制御しながら、外筒つきミニモジュールの内腔に導入した。中空糸膜外面から得られる濾過液を、チップの側管から回収した。濾過は、中空糸膜面積1m2あたり50Lの濾液が得られるまで実施した。
10mM濃度のMgSO4水溶液に、660nmでの吸光度が4.0となるように大腸菌を懸濁させておいた(以下E.Coli液と呼称する)。また、寒天培地、トップアガーを準備し、あらかじめ50℃に暖めておいた。特にトップアガーは、流動性を保っておくよう注意した。試験用ファージ液をBSA溶液で適当に希釈した液10μLと、E.Coli液50μLを混和し、37℃で20分インキュベートして大腸菌にファージを感染させた。インキュベート完了後、この混合液全量を、トップアガー3mLと混和し、速やかに全量を寒天培地上に展開した。寒天培地上でトップアガーが完全に固化した後、37℃で2~4時間インキュベートした。インキュベート完了後、寒天培地上のプラーク数をカウントし、希釈倍率を考慮して試験用ファージ液の力価(以下Tpreと略記する)[pfu/mL]を算出した。同様の手法で濾液のファージ力価(以下Tpostと略記する)を得た。
次式[7]により中空糸膜のファージクリアランス指数を算出した。ここで、Tpre[pfu/mL]とは評価用中空糸膜に導入した試験用ファージ液の力価を、Tpost[pfu/mL]とは試験用ファージ液を評価用中空糸膜で濾過して得られた濾液のファージ力価である。
ファージクリアランス指数 [LRV] = log10(Tpre/Tpost) [7]
上記と同様の方法で、中空糸膜面積1m2あたりの濾過量が200Lを超えた時点から濾液を回収し、この回収濾液を使用して上記の方法によりファージクリアランス指数を求めた。
PES(BASF社製Ultrason(商品名) E6020P)20重量部、BASF社製PVP(Luvitec(商品名)K90PH)6重量部、三菱化学社製NMP33.3重量部、三井化学社製TEG40.7重量部を55℃で6時間にわたって混合、溶解し均一な溶液を得た。この際、系内は減圧、窒素送入を数回繰り返して窒素置換し、密閉した状態で溶液の調製を行った。溶液調製後、55℃で常圧-0.09MPaまで減圧した後、溶媒等が揮発して溶液組成が変化しないようにすぐに系内を密封して30分放置して脱泡を行った。さらに、溶液はタンクからノズルをつなぐ流路に設けられた減圧部分で連続的に脱泡された後、ノズルに導入した。この際、流路の温度は55℃、減圧部分の減圧度は常圧-0.015MPaであった。
乾燥方法を変更した以外は実施例1と同様にして中空糸膜(B)を得た。中空糸膜(B)は次の方法で乾燥することによって得た。高圧熱水処理の完了した中空糸膜束24本を棚板に載せ、60℃の温風を6時間通じて乾燥した。乾燥工程における中空糸膜表面の最高到達温度は60℃、乾燥中空糸膜の水分率は2.4%であった。中空糸膜(B)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表1にまとめて示した。また、免疫グロブリン濾過時間-スループットの関係は図6に示した。
ドラフト比を4.2に変更した以外は実施例1と同様にして中空糸膜(C)を得た。乾燥工程における中空糸膜表面の最高到達温度は60℃、乾燥中空糸膜の水分率は3.1%であった。中空糸膜(C)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表1にまとめて示した。また、免疫グロブリン濾過時間-スループットの関係は図6に示した。
製膜溶液の構成をPES(BASF社製Ultrason(商品名) E6020P)19重量部、BASF社製PVP(Luvitec(商品名)K90PH)6重量部、三菱化学社製NMP33.75重量部、三井化学社製TEG41.25重量部とし、ノズル温度を53℃に、外部凝固液の構成をNMP18重量部、TEG22重量部、RO水60重量部の混合液に、外部凝固液温度を50℃に、エアギャップ長を30mmとして中空糸膜のエアギャップ部滞留時間を0.08秒に設定した以外は実施例1と同様にして中空糸膜(D)を得た。乾燥工程における中空糸膜表面の最高到達温度は60℃、乾燥中空糸膜の水分率は3.6%であった。中空糸膜(D)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表1にまとめて示した。また、免疫グロブリン濾過時間-スループットの関係は図6に示した。
製膜溶液の構成をPES(住友ケムテック社製スミカエクセル(商品名)5200P)20重量部、BASF社製PVP(Luvitec(商品名)K90PH)6重量部、三菱化学社製NMP33.3重量部、三井化学社製TEG40.7重量部とし、ノズル温度を53℃に、外部凝固液の構成をNMP18重量部、TEG22重量部、RO水60重量部の混合液にした以外は実施例1と同様にして中空糸膜(E)を得た。乾燥工程における中空糸膜表面の最高到達温度は60℃、乾燥中空糸膜の水分率は2.9%であった。中空糸膜(E)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表1にまとめて示した。また、免疫グロブリン濾過時間-スループットの関係は図6に示した。
製膜溶液の構成をPSf(アモコ社製P-3500)20重量部、BASF社製PVP(Luvitec(商品名)K90PH)6重量部、三菱化学社製NMP33.3重量部、三井化学社製TEG40.7重量部とし、ノズル温度を56℃に、外部凝固液の構成をNMP18重量部、TEG22重量部、RO水60重量部の混合液にした以外は実施例1と同様にして中空糸膜(F)を得た。乾燥工程における中空糸膜表面の最高到達温度は60℃、乾燥中空糸膜の水分率は3.6%であった。中空糸膜(F)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表1にまとめて
示した。また、免疫グロブリン濾過時間-スループットの関係は図6に示した。
PES(BASF社製Ultrason(商品名) E6020P)20重量部、BASF社製PVP(Luvitec(商品名)K90PH)6重量部、三菱化学社製NMP33.3重量部、三井化学社製TEG40.7重量部を55℃で6時間にわたって混合、溶解し均一な溶液を得た。この際、系内は減圧、窒素送入を数回繰り返して窒素置換し、密閉した状態で溶液の調製を行った。溶液調製後、55℃で常圧-0.09MPaまで減圧した後、溶媒等が揮発して溶液組成が変化しないようにすぐに系内を密封して30分放置して脱泡を行った。さらに、溶液はタンクからノズルをつなぐ流路に設けられた減圧部分で連続的に脱泡された後、ノズルに導入した。この際、流路の温度は55℃、減圧部分の減圧度は常圧-0.015MPaであった。
製膜溶液の構成をPES(BASF社製Ultrason(商品名) E6020P)20重量部、BASF社製PVP(Luvitec(商品名)K90PH)1重量部、三菱化学社製NMP35.55重量部、三井化学社製TEG43.45重量部とし、ノズル温度を60℃に、外部凝固液をRO水に、中空糸膜の洗浄槽でのネルソン・ローラー走行を実施せず洗浄槽を1回走行させて、洗浄槽内での滞留時間を3秒に設定した以外は実施例1と同様にして中空糸膜(H)を得た。乾燥工程における中空糸膜表面の最高到達温度は60℃、乾燥中空糸膜の水分率は3.0%であった。中空糸膜(H)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表2にまとめて示した。また、免疫グロブリン濾過時間-スループットの関係は図7に示した。
製膜溶液の構成をPES(BASF社製Ultrason(商品名) E6020P)20重量部、BASF社製PVP(Luvitec(商品名)K90PH)3重量部、三菱化学社製NMP34.65重量部、三井化学社製TEG42.35重量部とし、芯液をNMP1重量部、TEG4重量部の混合液体とし、外部凝固液をNMP27重量部、TEG33重量部、RO水40重量部の混合液とし、外部凝固液温度を55℃に設定した以外は比較例1と同様にして中空糸膜(I)を得た。乾燥工程における中空糸膜表面の最高到達温度は60℃、乾燥中空糸膜の水分率は3.0%であった。中空糸膜(I)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表2にまとめて示した。また、免疫グロブリン濾過時間-スループットの関係は図7に示した。
1回目の高圧熱水処理の浸漬液にグリセリンを添加しなかったこと、乾燥方法を変更したこと以外は実施例1と同様にして中空糸膜(J)を得た。中空糸膜(J)は次の方法で乾燥することによって得た。高圧熱水処理の完了した中空糸膜束24本を棚板に載せ、80℃の温風を20時間通じて乾燥した。乾燥工程における中空糸膜表面の最高到達温度は80℃、乾燥中空糸膜の水分率は0.2%であった。中空糸膜(J)の特徴・特性、実施例1と同様に測定したP5およびP60、φX174-CL50およびφX174-CL200は表2にまとめて示した。また、免疫グロブリン濾過時間-スループットの関係は図7に示した。
PES(BASF社製Ultrason(商品名) E6020P)20重量部、BASF社製PVP(Luvitec(商品名)K90PH)6重量部、三菱化学社製NMP33.3重量部、三井化学社製TEG40.7重量部を55℃で6時間にわたって混合、溶解し均一な溶液を得た。この際、系内は減圧、窒素送入を数回繰り返して窒素置換し、密閉した状態で溶液の調製を行った。溶液調製後、55℃で常圧-0.09MPaまで減圧した後、溶媒等が揮発して溶液組成が変化しないようにすぐに系内を密封して30分放置して脱泡を行った。さらに、溶液はタンクからノズルをつなぐ流路に設けられた減圧部分で連続的に脱泡された後、ノズルに導入した。この際、流路の温度は55℃、減圧部分の減圧度は常圧-0.015MPaであった。
Claims (6)
- 疎水性高分子と親水性高分子を含んでなり、純水の透過速度が10~300L/(h・m2・bar)であり、0.5%免疫グロブリン溶液をデッドエンドで60分にわたり1.0barの定圧濾過した時、濾過時間と濾液回収積算量が実質的に直線関係にあることを特徴とするタンパク質含有液処理用多孔質中空糸膜。
- 膜厚部分の中心領域が実質的に均質な構造からなり、かつ膜厚部分がマクロボイドを持たない構造からなることを特徴とする請求項1に記載のタンパク質含有液処理用多孔質中空糸膜。
- 内径が150~400μm、膜厚が40~200μmであることを特徴とする請求項1または2に記載のタンパク質含有液処理用多孔質中空糸膜。
- 疎水性高分子がポリスルホン系高分子であることを特徴とする請求項1~3いずれかに記載のタンパク質含有液処理用多孔質中空糸膜。
- 親水性高分子がポリビニルピロリドンであることを特徴とする請求項1~4いずれかに記載のタンパク質含有液処理用多孔質中空糸膜。
- タンパク質溶液からウィルスを分離するために使用される膜であることを特徴とする請求項1~5いずれかに記載のタンパク質含有液処理用多孔質中空糸膜。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK11753337.2T DK2545986T3 (da) | 2010-03-09 | 2011-03-08 | Porøs hulfibermembran til behandling af en protein-holdig væske |
EP11753337.2A EP2545986B1 (en) | 2010-03-09 | 2011-03-08 | Porous hollow fiber membrane for treatment of protein-containing liquid |
US13/578,416 US9492794B2 (en) | 2010-03-09 | 2011-03-08 | Porous hollow fiber membrane for treatment of protein-containing liquid |
CA2792357A CA2792357C (en) | 2010-03-09 | 2011-03-08 | Porous hollow fiber membrane for treatment of protein-containing liquid |
AU2011225316A AU2011225316B2 (en) | 2010-03-09 | 2011-03-08 | Porous, hollow fiber membrane for liquid treatment containing protein |
JP2012504460A JP5754654B2 (ja) | 2010-03-09 | 2011-03-08 | タンパク質含有液処理用多孔質中空糸膜 |
CN201180011902.XA CN102892486B (zh) | 2010-03-09 | 2011-03-08 | 含蛋白质液处理用多孔中空纤维膜 |
KR1020127023273A KR20130014512A (ko) | 2010-03-09 | 2011-03-08 | 단백질 함유 액처리용 다공질 중공사막 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010051559 | 2010-03-09 | ||
JP2010-051559 | 2010-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011111679A1 true WO2011111679A1 (ja) | 2011-09-15 |
Family
ID=44563480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/055299 WO2011111679A1 (ja) | 2010-03-09 | 2011-03-08 | タンパク質含有液処理用多孔質中空糸膜 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9492794B2 (ja) |
EP (1) | EP2545986B1 (ja) |
JP (1) | JP5754654B2 (ja) |
KR (1) | KR20130014512A (ja) |
CN (1) | CN102892486B (ja) |
AU (1) | AU2011225316B2 (ja) |
CA (1) | CA2792357C (ja) |
DK (1) | DK2545986T3 (ja) |
WO (1) | WO2011111679A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014077095A1 (ja) * | 2012-11-15 | 2014-05-22 | 東洋紡株式会社 | 多孔質中空糸膜 |
WO2016031834A1 (ja) * | 2014-08-25 | 2016-03-03 | 旭化成メディカル株式会社 | 多孔質膜 |
WO2016117565A1 (ja) * | 2015-01-19 | 2016-07-28 | 旭化成メディカル株式会社 | 多孔質中空糸濾過膜 |
JP2017014441A (ja) * | 2015-07-04 | 2017-01-19 | 永嶋 良一 | 成形体の製造方法 |
JP6327543B1 (ja) * | 2017-07-13 | 2018-05-23 | 東洋紡株式会社 | 抗炎症性を有する中空糸膜およびその製造方法 |
WO2019225730A1 (ja) | 2018-05-24 | 2019-11-28 | 東レ株式会社 | 多孔質中空糸膜 |
JP2019537508A (ja) * | 2016-11-17 | 2019-12-26 | ケー. シースジ,ジェイラジ | 高分子量の親水性添加剤を含有するイソポーラス自己集合ブロックコポリマーフィルム及びその製造方法 |
US10829514B2 (en) | 2014-04-11 | 2020-11-10 | Asahi Kasei Medical Co., Ltd. | Virus removal membrane |
US11466134B2 (en) | 2011-05-04 | 2022-10-11 | Cornell University | Multiblock copolymer films, methods of making same, and uses thereof |
US11567072B2 (en) | 2017-02-22 | 2023-01-31 | Terapore Technologies, Inc. | Ligand bound MBP membranes, uses and method of manufacturing |
US11571667B2 (en) | 2018-03-12 | 2023-02-07 | Terapore Technologies, Inc. | Isoporous mesoporous asymmetric block copolymer materials with macrovoids and method of making the same |
US11572424B2 (en) | 2017-05-12 | 2023-02-07 | Terapore Technologies, Inc. | Chemically resistant fluorinated multiblock polymer structures, methods of manufacturing and use |
US11628409B2 (en) | 2016-04-28 | 2023-04-18 | Terapore Technologies, Inc. | Charged isoporous materials for electrostatic separations |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6206089B2 (ja) * | 2013-04-23 | 2017-10-04 | Jnc株式会社 | 多糖類モノリス構造体及びその製造方法 |
BR112015030619B1 (pt) * | 2013-06-12 | 2022-02-22 | Kimberly-Clark Worldwide, Inc | Artigo absorvente |
US11186927B2 (en) * | 2014-06-06 | 2021-11-30 | Kimberly Clark Worldwide, Inc. | Hollow porous fibers |
JP6397781B2 (ja) * | 2015-02-26 | 2018-09-26 | 旭化成メディカル株式会社 | 濃縮器 |
CN109070010B (zh) * | 2016-03-11 | 2021-09-10 | 旭化成株式会社 | 多孔膜、多孔膜组件、多孔膜的制造方法、澄清的液体的制造方法及啤酒的制造方法 |
DE102016224627A1 (de) * | 2016-12-09 | 2018-06-14 | Fresenius Medical Care Deutschland Gmbh | Hohlfasermembran mit verbesserter Trennleistung und Herstellung einer Hohlfasermembran mit verbesserter Trennleistung |
JP6573650B2 (ja) | 2017-09-15 | 2019-09-11 | 住友化学株式会社 | ガス分離方法 |
JP6573942B2 (ja) * | 2017-09-15 | 2019-09-11 | 住友化学株式会社 | ガス分離方法 |
US20220168694A1 (en) * | 2019-03-29 | 2022-06-02 | Asahi Kasei Medical Co., Ltd. | Porous membrane |
CN117679962B (zh) * | 2023-09-29 | 2024-05-14 | 杭州科百特过滤器材有限公司 | 一种纤维素除病毒滤膜及其制备工艺和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11332980A (ja) * | 1998-05-27 | 1999-12-07 | Toray Ind Inc | 中空糸膜の製膜方法 |
WO2004035180A1 (ja) * | 2002-10-18 | 2004-04-29 | Asahi Kasei Pharma Corporation | 親水性微多孔膜 |
JP2008237987A (ja) * | 2007-03-26 | 2008-10-09 | Toyobo Co Ltd | 中空糸膜の製造方法および中空糸膜 |
WO2008156124A1 (ja) * | 2007-06-19 | 2008-12-24 | Asahi Kasei Kabushiki Kaisha | 免疫グロブリン1量体の分離方法 |
WO2009051168A1 (ja) * | 2007-10-19 | 2009-04-23 | Toyo Boseki Kabushiki Kaisha | 液体処理用の中空糸膜 |
WO2009104705A1 (ja) * | 2008-02-21 | 2009-08-27 | 東洋紡績株式会社 | 耐ファウリング性に優れる中空糸型限外ろ過膜 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4808315A (en) | 1986-04-28 | 1989-02-28 | Asahi Kasei Kogyo Kabushiki Kaisha | Porous hollow fiber membrane and a method for the removal of a virus by using the same |
US7144505B2 (en) | 1997-09-18 | 2006-12-05 | Baxter International Inc. | Melt-spun polysulfone semipermeable membranes and methods for making the same |
US7140496B2 (en) | 2001-08-01 | 2006-11-28 | Asahi Kasei Medical Co., Ltd. | Multilayer microporous membrane |
CA2498244C (en) * | 2002-09-12 | 2012-03-06 | Teruhiko Oishi | Plasma purification membrane and plasma purification system |
WO2005025649A1 (ja) | 2003-08-22 | 2005-03-24 | Toyo Boseki Kabushiki Kaisha | ポリスルホン系選択透過性中空糸膜およびその製造方法 |
CN100515548C (zh) * | 2004-08-10 | 2009-07-22 | 尼普洛株式会社 | 聚砜系选择渗透性中空纤维膜组件及其制造方法 |
US7476636B2 (en) * | 2004-12-03 | 2009-01-13 | L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploration Des Procedes Georges Claude | Method of making mixed matrix membranes using electrostatically stabilized suspensions |
US20070084788A1 (en) | 2005-10-14 | 2007-04-19 | Millipore Corporation | Ultrafiltration membranes and methods of making and use of ultrafiltration membranes |
US8881915B2 (en) * | 2006-04-26 | 2014-11-11 | Toyo Boseki Kabushiki Kaisha | Polymeric porous hollow fiber membrane |
JP2008094722A (ja) | 2006-10-05 | 2008-04-24 | Benesis Corp | 免疫グロブリン製剤の製造方法 |
US8741600B2 (en) | 2007-06-19 | 2014-06-03 | Asahi Kasei Kabushiki Kaisha | Method for separation of immunoglobulin monomers |
TW201006517A (en) * | 2008-05-22 | 2010-02-16 | Asahi Kasei Medical Co Ltd | Filtration method |
-
2011
- 2011-03-08 EP EP11753337.2A patent/EP2545986B1/en active Active
- 2011-03-08 US US13/578,416 patent/US9492794B2/en active Active
- 2011-03-08 WO PCT/JP2011/055299 patent/WO2011111679A1/ja active Application Filing
- 2011-03-08 JP JP2012504460A patent/JP5754654B2/ja active Active
- 2011-03-08 DK DK11753337.2T patent/DK2545986T3/da active
- 2011-03-08 KR KR1020127023273A patent/KR20130014512A/ko not_active Application Discontinuation
- 2011-03-08 CA CA2792357A patent/CA2792357C/en active Active
- 2011-03-08 CN CN201180011902.XA patent/CN102892486B/zh active Active
- 2011-03-08 AU AU2011225316A patent/AU2011225316B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11332980A (ja) * | 1998-05-27 | 1999-12-07 | Toray Ind Inc | 中空糸膜の製膜方法 |
WO2004035180A1 (ja) * | 2002-10-18 | 2004-04-29 | Asahi Kasei Pharma Corporation | 親水性微多孔膜 |
JP2008237987A (ja) * | 2007-03-26 | 2008-10-09 | Toyobo Co Ltd | 中空糸膜の製造方法および中空糸膜 |
WO2008156124A1 (ja) * | 2007-06-19 | 2008-12-24 | Asahi Kasei Kabushiki Kaisha | 免疫グロブリン1量体の分離方法 |
WO2009051168A1 (ja) * | 2007-10-19 | 2009-04-23 | Toyo Boseki Kabushiki Kaisha | 液体処理用の中空糸膜 |
WO2009104705A1 (ja) * | 2008-02-21 | 2009-08-27 | 東洋紡績株式会社 | 耐ファウリング性に優れる中空糸型限外ろ過膜 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466134B2 (en) | 2011-05-04 | 2022-10-11 | Cornell University | Multiblock copolymer films, methods of making same, and uses thereof |
US10577393B2 (en) | 2012-11-15 | 2020-03-03 | Toyobo Co., Ltd. | Porous hollow fiber membrane |
EP2896451B1 (en) * | 2012-11-15 | 2023-07-12 | Toyobo Co., Ltd. | Porous hollow fiber membrane |
WO2014077095A1 (ja) * | 2012-11-15 | 2014-05-22 | 東洋紡株式会社 | 多孔質中空糸膜 |
US10829514B2 (en) | 2014-04-11 | 2020-11-10 | Asahi Kasei Medical Co., Ltd. | Virus removal membrane |
KR20160137628A (ko) | 2014-08-25 | 2016-11-30 | 아사히 가세이 메디컬 가부시키가이샤 | 다공질막 |
JPWO2016031834A1 (ja) * | 2014-08-25 | 2017-06-15 | 旭化成メディカル株式会社 | 多孔質膜 |
KR20190037350A (ko) | 2014-08-25 | 2019-04-05 | 아사히 가세이 메디컬 가부시키가이샤 | 다공질막 |
WO2016031834A1 (ja) * | 2014-08-25 | 2016-03-03 | 旭化成メディカル株式会社 | 多孔質膜 |
US11338248B2 (en) | 2014-08-25 | 2022-05-24 | Asahi Kasei Medical Co., Ltd. | Porous membrane |
JPWO2016117565A1 (ja) * | 2015-01-19 | 2017-09-28 | 旭化成メディカル株式会社 | 多孔質中空糸濾過膜 |
WO2016117565A1 (ja) * | 2015-01-19 | 2016-07-28 | 旭化成メディカル株式会社 | 多孔質中空糸濾過膜 |
JP2017014441A (ja) * | 2015-07-04 | 2017-01-19 | 永嶋 良一 | 成形体の製造方法 |
US11628409B2 (en) | 2016-04-28 | 2023-04-18 | Terapore Technologies, Inc. | Charged isoporous materials for electrostatic separations |
US11401411B2 (en) | 2016-11-17 | 2022-08-02 | Terapore Technologies, Inc. | Isoporous self-assembled block copolymer films containing high molecular weight hydrophilic additives and methods of making the same |
JP7104040B2 (ja) | 2016-11-17 | 2022-07-20 | ケー. シースジ,ジェイラジ | 高分子量の親水性添加剤を含有するイソポーラス自己集合ブロックコポリマーフィルム及びその製造方法 |
US11802200B2 (en) | 2016-11-17 | 2023-10-31 | Terapore Technologies, Inc. | Isoporous self-assembled block copolymer films containing high molecular weight hydrophilic additives and methods of making the same |
JP2019537508A (ja) * | 2016-11-17 | 2019-12-26 | ケー. シースジ,ジェイラジ | 高分子量の親水性添加剤を含有するイソポーラス自己集合ブロックコポリマーフィルム及びその製造方法 |
US11567072B2 (en) | 2017-02-22 | 2023-01-31 | Terapore Technologies, Inc. | Ligand bound MBP membranes, uses and method of manufacturing |
US11572424B2 (en) | 2017-05-12 | 2023-02-07 | Terapore Technologies, Inc. | Chemically resistant fluorinated multiblock polymer structures, methods of manufacturing and use |
JP2019018193A (ja) * | 2017-07-13 | 2019-02-07 | 東洋紡株式会社 | 抗炎症性を有する中空糸膜およびその製造方法 |
JP6327543B1 (ja) * | 2017-07-13 | 2018-05-23 | 東洋紡株式会社 | 抗炎症性を有する中空糸膜およびその製造方法 |
US11571667B2 (en) | 2018-03-12 | 2023-02-07 | Terapore Technologies, Inc. | Isoporous mesoporous asymmetric block copolymer materials with macrovoids and method of making the same |
KR20210011372A (ko) | 2018-05-24 | 2021-02-01 | 도레이 카부시키가이샤 | 다공질 중공사막 |
WO2019225730A1 (ja) | 2018-05-24 | 2019-11-28 | 東レ株式会社 | 多孔質中空糸膜 |
Also Published As
Publication number | Publication date |
---|---|
KR20130014512A (ko) | 2013-02-07 |
US9492794B2 (en) | 2016-11-15 |
EP2545986B1 (en) | 2020-12-09 |
CA2792357C (en) | 2021-10-26 |
CA2792357A1 (en) | 2011-09-15 |
AU2011225316B2 (en) | 2014-04-17 |
DK2545986T3 (da) | 2021-03-08 |
CN102892486A (zh) | 2013-01-23 |
CN102892486B (zh) | 2014-11-26 |
US20120305472A1 (en) | 2012-12-06 |
AU2011225316A1 (en) | 2012-08-30 |
JPWO2011111679A1 (ja) | 2013-06-27 |
EP2545986A1 (en) | 2013-01-16 |
JP5754654B2 (ja) | 2015-07-29 |
EP2545986A4 (en) | 2015-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5754654B2 (ja) | タンパク質含有液処理用多孔質中空糸膜 | |
JP5207150B2 (ja) | 多孔質中空糸膜およびタンパク質含有液処理用多孔質中空糸膜 | |
JP5504560B2 (ja) | 液体処理用の中空糸膜 | |
JP5403444B1 (ja) | 多孔質中空糸膜 | |
JP6024660B2 (ja) | 多孔質中空糸膜 | |
EP2845641B1 (en) | Permselective asymmetric membranes with high molecular weight polyvinylpyrrolidone, the preparation and use thereof | |
EP2113298A1 (en) | Hollow fibre membrane with improved permeability and selectivity | |
EP3216515B1 (en) | Hollow fiber filtration membrane | |
JP6433513B2 (ja) | 多孔質中空糸濾過膜 | |
JP5835659B2 (ja) | タンパク質含有液処理用多孔質中空糸膜 | |
WO2016113964A1 (ja) | 多孔質中空糸膜 | |
JP3934340B2 (ja) | 血液浄化器 | |
WO2016182015A1 (ja) | 多孔質中空糸膜及びその製造方法 | |
JP2008194647A (ja) | 中空糸膜 | |
JP2011020071A (ja) | ポリスルホン系中空糸膜の製造方法 | |
JP2001038172A (ja) | 中空糸型選択分離膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180011902.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11753337 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012504460 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011225316 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13578416 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2011225316 Country of ref document: AU Date of ref document: 20110308 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2792357 Country of ref document: CA Ref document number: 20127023273 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011753337 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8456/CHENP/2012 Country of ref document: IN |